RecruitingNCT05131100

Korean Regulatory Post Marketing Surveillance for Somavert

Korean Post-marketing Surveillance for Somavert

Sponsor

Pfizer

Enrollment

100 participants

Start Date

Jul 13, 2022

Study Type

OBSERVATIONAL

Conditions

Acromegaly

Summary

Non-interventional observational study, to identify safety and effectiveness of Somavert during the post-marketing period based on the Korean RMP as required by the regulations of Ministry of Food and Drug Safety (MFDS)

Eligibility

Min Age: 18 Years

Inclusion Criteria1

All patients who have been prescribed as per local label and investigators' judgement under the setting of routine practice in Korea who are eligible.

Exclusion Criteria1

Patients who are contraindicated for Somavert

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSomavert

As provided in real world practice

Locations(1)

Pfizer

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05131100

Related Trials

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

NCT0693062571 locations

ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly

NCT0703742045 locations